DCTH May 2024 7.500 call
| Previous Close | 0.0500 |
| Open | 0.0900 |
| Bid | 0.0500 |
| Ask | 0.1000 |
| Strike | 7.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0500 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 350 |
PR NewswireDelcath Systems to Host First Quarter 2024 Earnings Call
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.
- PR Newswire
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of results from the pivotal Phase 3 FOCUS study of HEPZATO KIT (melphalan/Hepatic Delivery System) in patients with unresectable metastatic Uveal Melanoma (mUM) on May 5, 2024 in the journal Annals of Surgical Oncology.
- PR Newswire
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in April 2024.
